Acalabrutinib 100 mg (Acazee / Calquence / Acabrunat) is a potent BTK inhibitor for treating certain blood cancers like CLL, SLL, and MCL. Prescription only; used under specialist supervision.
Share:
Acalabrutinib 100 mg (marketed under names like Acazee, Calquence, Acabrunat) is a targeted therapy used in the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). As a Bruton’s tyrosine kinase (BTK) inhibitor, it works by blocking BTK enzyme activity, which plays a crucial role in the survival and proliferation of malignant B cells.